Barrington Research Comments on Concentrix Q2 Earnings

Concentrix Co. (NASDAQ:CNXC - Free Report) - Equities research analysts at Barrington Research issued their Q2 2025 EPS estimates for Concentrix in a report released on Thursday, March 27th. Barrington Research analyst V. Colicchio anticipates that the company will earn $2.50 per share for the quarter. Barrington Research has a "Outperform" rating and a $54.00 price objective on the stock. The consensus estimate for Concentrix's current full-year earnings is $10.11 per share. Barrington Research also issued estimates for Concentrix's Q3 2025 earnings at $2.61 EPS, Q4 2025 earnings at $2.71 EPS and FY2026 earnings at $11.21 EPS.

Concentrix (NASDAQ:CNXC - Get Free Report) last released its earnings results on Wednesday, March 26th. The company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.58 by $0.21. Concentrix had a return on equity of 16.67% and a net margin of 2.61%. The business had revenue of $2.37 billion during the quarter, compared to analysts' expectations of $2.37 billion. During the same quarter last year, the firm posted $2.57 earnings per share. The firm's revenue was down 1.3% on a year-over-year basis.

CNXC has been the subject of a number of other reports. Bank of America raised their price target on shares of Concentrix from $58.00 to $59.00 and gave the stock a "neutral" rating in a report on Thursday, March 27th. Canaccord Genuity Group cut their price objective on shares of Concentrix from $100.00 to $80.00 and set a "buy" rating on the stock in a research report on Thursday, January 16th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $69.60.

Remove Ads

Concentrix Trading Down 7.0 %

Shares of CNXC stock traded down $3.78 during trading hours on Monday, hitting $50.43. 1,286,343 shares of the company were exchanged, compared to its average volume of 678,586. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.42 and a current ratio of 1.42. Concentrix has a fifty-two week low of $36.28 and a fifty-two week high of $77.00. The company has a 50 day simple moving average of $48.30 and a two-hundred day simple moving average of $47.36. The firm has a market cap of $3.24 billion, a P/E ratio of 13.59, a P/E/G ratio of 0.63 and a beta of 0.69.

Concentrix Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 6th. Shareholders of record on Friday, April 25th will be paid a $0.3328 dividend. This represents a $1.33 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend is Friday, April 25th. Concentrix's dividend payout ratio (DPR) is 33.33%.

Insider Activity

In other Concentrix news, Director Kathryn Hayley purchased 500 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The shares were acquired at an average price of $50.22 per share, with a total value of $25,110.00. Following the transaction, the director now owns 3,034 shares in the company, valued at $152,367.48. The trade was a 19.73 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.20% of the company's stock.

Institutional Trading of Concentrix

Several institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in Concentrix by 582.5% during the first quarter. Versant Capital Management Inc now owns 2,109 shares of the company's stock worth $117,000 after buying an additional 1,800 shares in the last quarter. CSS LLC IL bought a new stake in shares of Concentrix in the 4th quarter worth $355,000. PharVision Advisers LLC purchased a new stake in shares of Concentrix in the fourth quarter valued at about $465,000. Paradigm Capital Management Inc. NY lifted its position in shares of Concentrix by 2.7% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 750,142 shares of the company's stock valued at $32,459,000 after purchasing an additional 19,418 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Concentrix by 15.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 124,769 shares of the company's stock worth $5,399,000 after purchasing an additional 17,019 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Concentrix

Concentrix Corporation engages in the provision of technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services, across various channels of communication, such as voice, chat, email, social media, asynchronous messaging, and custom applications.